Rosiglitazone increases matrix production and quenches inflammation: studies in human cells

Solini, Anna; Santini, Eleonora; Madec, Stéphanie; Nannipieri, Monica; Bonotti, A; Cuccato, Sabina; Ferrannini, Ele

doi:10.1002/dmrr.781

Cited by 4 publications

(2 citation statements)

References 45 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Moreover, rosiglitazone did not have any additional effects on KLF5 expression when ERK1/2 was blocked, which suggests that ERK1/2 signaling, at least in part, may be involved in the inhibitory effect of PPAR-γ agonist on Ang II-induced KLF5 expression in VSMCs. In accordance with our study, previous studies have demonstrated that PPAR-γ activation may inhibit Ang II induced ERK1/2 activation in endothelial cells[ 41 , 42 ] and VSMCs [ 43 , 44 ]. Recently, Kim et al has showed the similar result that rosiglitazone might attenuate VSMCs proliferation at least by inhibit ERK1/2 activation and other cell signaling such as, mTOR-p70S6K and -4EBP1 systems[ 45 ].…”

Section: Discussionsupporting

confidence: 93%

Rosiglitzone Suppresses Angiotensin II-Induced Production of KLF5 and Cell Proliferation in Rat Vascular Smooth Muscle Cells

et al. 2015

View full text Add to dashboard Cite

Krüppel-like factor (KLF) 5, which initiates vascular smooth muscle cell (VSMC) proliferation, also participates in Angiotensin (Ang) II-induced vascular remodeling. The protective effect of rosiglitazone on vascular remodeling may be due to their impact on VSMC proliferation. However, the underlying mechanisms involved remain unclear. This study was designed to investigate whether the antiproliferation effects of rosiglitazone are mediated by regulating Ang II/KLF5 response. We found that, in aortas of Ang II-infused rats, vascular remodeling and KLF5 expression were markedly increased, and its target gene cyclin D1 was overexpressed. Co-treatment with rosiglitazone diminished these changes. In growth-arrested VSMCs, PPAR-γ agonists (rosiglitazone and 15d-PGJ2) dose-dependently inhibited Ang II-induced cell proliferation and expression of KLF5 and cyclin D1. Moreover, these effects were attenuated by the PPAR-γ antagonists GW9662, bisphenol A diglycidyl ether and PPAR-γ specific siRNA. Furthermore, rosiglitazone inhibited Ang II-induced phosphorylation of protein kinase C (PKC) ζ and extracellular signal-regulated kinase (ERK) 1/2 and activation of early growth response protein (Egr). In conclusion, in Ang II-stimulated VSMCs, rosiglitazone might have an antiproliferative effect through mechanisms that include reducing KLF5 expression, and a crosstalk between PPAR-γ and PKCζ/ERK1/2/Egr may be involved in. These findings not only provide a previously unrecognized mechanism by which PPAR-γ agonists inhibit VSMC proliferation, but also document a novel evidence for the beneficial vascular effect of PPAR-γ activation.

show abstract

Section: Discussionsupporting

confidence: 93%

Rosiglitzone Suppresses Angiotensin II-Induced Production of KLF5 and Cell Proliferation in Rat Vascular Smooth Muscle Cells

et al. 2015

View full text Add to dashboard Cite

show abstract

“…The previous study showed that Cytokine-cytokine receptor interaction regulates immune response and inflammation by activating various signaling pathways, including the MAPK pathway, cytokines such as IL-6 and TNF-α activate the MAPK pathway, leading to increased inflammatory response, which plays an important role in the development of autoimmune diseases and cancers, and that enrichment of this pathway in high-risk groups may imply a stronger inflammatory state or aberrant immune activation 41 , 42 . ECM receptor interaction and Focal adhesion both are associated with extracellular matrix (ECM) and cell adhesion, and previous reports have shown that MAPK signaling is associated with ECM production and degradation, thereby promoting cell migration and proliferation 43 – 46 , which may be a reflection of the worse prognosis of high-risk groups. Cytoskeletal regulation is critical for cell shape, motility, and division.…”

Section: Discussionmentioning

confidence: 99%

Predicting bladder cancer survival with high accuracy: insights from MAPK pathway-related genes

Cheng,

Zhou,

et al. 2024

Sci Rep

View full text Add to dashboard Cite

The mitogen-activated protein kinase (MAPK) pathway plays a critical role in tumor development and immunotherapy. Nevertheless, additional research is necessary to comprehend the relationship between the MAPK pathway and the prognosis of bladder cancer (BLCA), as well as its influence on the tumor immune microenvironment. To create prognostic models, we screened ten genes associated with the MAPK pathway using COX and least absolute shrinkage and selection operator (LASSO) regression analysis. These models were validated in the Genomic Data Commons (GEO) cohort and further examined for immune infiltration, somatic mutation, and drug sensitivity characteristics. Finally, the findings were validated using The Human Protein Atlas (HPA) database and through Quantitative Real-time PCR (qRT-PCR). Patients were classified into high-risk and low-risk groups based on the prognosis-related genes of the MAPK pathway. The high-risk group had poorer overall survival than the low-risk group and showed increased immune infiltration compared to the low-risk group. Additionally, the nomograms built using the risk scores and clinical factors exhibited high accuracy in predicting the survival of BLCA patients. The prognostic profiling of MAPK pathway-associated genes represents a potent clinical prediction tool, serving as the foundation for precise clinical treatment of BLCA.

show abstract

Current literature in diabetes

2008

Diabetes Metabolism Res

View full text Add to dashboard Cite

In order to keep subscribers up‐to‐date with the latest developments in their field, John Wiley & Sons are providing a current awareness service in each issue of the journal. The bibliography contains newly published material in the field of diabetes/metabolism. Each bibliography is divided into 26 sections: 1 Reviews; 2 General; 3 Genetics; 4 Epidemiology; 5 Immunology; 6 Obesity; 7 Prediction and Prevention; 8 Intervention: a) General; b) Care; c) Drug Therapy; d)Economics; e) Gene therapy; f) Nursing; g) Nutrition; h) Surgery; i) Transplantation; 9 Pathology and Complications: a) General; b) Cardiovascular; c) Eye disease; d) Gestational and fetal; e) Neurological; f) Podiatrical; g) Renal; 10 Endocrinology & Metabolism; 11 Experimental Studies; 12 Diagnosis and Techniques. Within each section, articles are listed in alphabetical order with respect to author

show abstract

Rosiglitazone increases matrix production and quenches inflammation: studies in human cells

Cited by 4 publications

References 45 publications

Rosiglitzone Suppresses Angiotensin II-Induced Production of KLF5 and Cell Proliferation in Rat Vascular Smooth Muscle Cells

Rosiglitzone Suppresses Angiotensin II-Induced Production of KLF5 and Cell Proliferation in Rat Vascular Smooth Muscle Cells

Predicting bladder cancer survival with high accuracy: insights from MAPK pathway-related genes

Current literature in diabetes

Contact Info

Product

Resources

About